ARCTArcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA techno…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Moderna And Merck's Cancer Vaccine: Are Investors Putting The Cart Before The Horse? Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run. | ||
 Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Cana | ||
 Arcturus Therapeutics Q2 Earnings Call Highlights Arcturus Therapeutics (NASDAQ:ARCT) reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA | ||
 Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Exelixis (EXEL) Tops Q2 Earnings Estimates Exelixis (EXEL) delivered earnings and revenue surprises of +5.81% and -0.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||